系统性红斑狼疮患者血清γ干扰素诱导的蛋白10表达水平与疾病活动的关系

被引：9

作者：

刘中娟

林嘉友

倪安平

宋耀虹

沈瑛

张时民

机构：

[1] 中国医学科学院中国协和医科大学北京协和医院检验科

[2] 中国医学科学院基础医学研究所免疫室

来源：

中华检验医学杂志 | 2005年 / 01期

关键词：

红斑狼疮,系统性; 狼疮肾炎; γ干扰素诱导的蛋白10;

D O I：

暂无

中图分类号：

R593.241 [];

学科分类号：

1002 ; 100201 ;

摘要：

目的　探讨血清γ干扰素诱导的蛋白 10 (IP 10 )水平 ,与红斑狼疮 (SLE)疾病活动的关系及其在SLE肾损伤中的可能作用。方法　收集了 112例SLE患者及 4 0名正常健康人和 30例类风湿性关节炎 (RA)患者血清。应用ELISA测定血清IP 10水平。结果　SLE活动组血清IP 10水平 (5 0 8 7± 2 5 2 4 ) μg/L较非活动组 (32 2 2± 95 9) μg/L和对照组 (12 4 9± 4 1 3) μg/L明显升高 (P<0 0 0 1)。活动性狼疮肾炎 (LN)组IP 10水平 (5 5 0 9± 2 0 6 1) μg/L与活动性无肾损伤组 (35 4 8±10 5 3) μg/L及对照组比较其差异均具有统计学意义 (P <0 0 0 1)。特别是Ⅲ型和Ⅳ型LN患者血清IP 10水平 (6 2 9 85± 16 4 ) μg/L升高最为显著 ,与Ⅱ型和Ⅴ型LN(30 2 9± 2 0 7 1) μg/L相比其差异具有统计学意义 (P <0 0 1)。另外 ,血清IP 10水平随着SLE疾病活动水平明显升高 ,与总的SLEDAI评分密切相关 (r=0 6 312 ,P <0 0 0 1) ,与SLEDAI肾评分亦密切相关 (r =0 6 880 ,P <0 0 0 1)。结论　以上结果表明IP 10可能在SLE肾损伤中起着十分重要的作用 ,血清IP 10水平与SLE疾病活动密切相关 ,可作为SLE疾病活动、尤其是监测狼疮肾损伤的重要指标。

引用

页码：51 / 54

页数：4

共 10 条

[1]

Chemokine and chemokine receptor expression in a novel human messangial cell line. Banas B,Luckow B,Moller M,et al. Journal of the American Society of Nephrology . 1999

[2]

The immunobiology of inter-feron-gamma inducible protein 10kD(IP-10):a novel,pleiotropicmember of the C-X-C chemokine superfamily. Neville L F,Mathiak G,Bagasra O. Cytokine and Growth Factor Reviews . 1997

[3]

Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Eriksson C,Eneslatt K,Ivanoff J,et al. Lupus . 2003

[4]

Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants,TARC and MDC, are elevated in patients with systemic sclerosis. Fujii H,Shimada Y,Hasegawa M,et al. Journal of Dermatological Science . 2004

[5]

Selective accumulation of CD4+ T lymphocytes into renal tissue of patients with lupus nephritis. Yamada M,Yagita H,Inoue H,et al. Arthritis and Rheumatism . 2002

[6]

Roles of CCR2 and CXCR3 in the T cell mediated response occurring during lupus flares. Zahir A,Christophe C,Sophie F,et al. Arthritis and Rheumatism . 2003

[7]

Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Masutani K,Akahoshi M,Tsuruya K,et al. Arthritis and Rheumatism . 2001

[8]

Chemokines diseases. Gerard C,Rollins BJ. Nature Immunology . 2001

[9]

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Hochberg,MC. Arthritis and Rheumatism . 1997

[10]

The committee on prognosis studies in SLE.Derivation of the SLEDAI: a disease activity index for lupus patients. Bombardier C,Gladmann DD,Urowitz MB,et al. Arthritis and Rheumatism . 1992

← 1 →